1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 2-2
&NA;,
Preview
|
PDF (796KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 3-3
&NA;,
Preview
|
PDF (710KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
A role for insulin-sensitising agents in PCOS? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 4-4
&NA;,
Preview
|
PDF (762KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
HIV-1 reservoir may encourage patient compliance |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 5-5
&NA;,
Preview
|
PDF (715KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
Anastrozole cost effective in advanced breast cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 6-7
Tracey Wright,
Preview
|
PDF (1535KB)
|
|
摘要:
Economic analysis of phase III clinical data indicates that anastrozole is a cost-effective treatment for patients with advanced breast cancer. Anastrozole was associated with an incremental cost-effectiveness ratio of £1608 per additional life-year gained, compared with megestrol, reported Mr JS Brown from Zeneca Pharmaceuticals, UK, at the First European Conference on the Economics of Cancer [Belgium, Brussels; November 1997]. For most patients with advanced disease, the main aim of treatment is palliation, using endocrine therapy to restrict tumour growth and minimise symptoms.*Until recently, standard second-line therapy has been with either a progesterone (e.g. megestrol or medroxyprogesterone) or a nonspecific aromatase inhibitor (e.g. aminoglutethimide).
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
… and prescribing improvement programme reduces costs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 7-7
&NA;,
Preview
|
PDF (784KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 8-8
&NA;,
Preview
|
PDF (724KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
Anti-TNF-&agr; treatments set to mop up in rheumatoid arthritis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 9-10
Amanda Cameron,
Preview
|
PDF (1600KB)
|
|
摘要:
It is generally agreed that no currently available drugs, including disease-modifying antirheumatic drugs (DMARDs), can reverse or halt the progression of rheumatoid arthritis (RA). In addition, DMARDs are slow to produce clinical benefits and have potentially serious adverse effects. It is not surprising, therefore, that rheumatologists are excited about new clinical trial results supporting prior evidence that treatments directed against tumour necrosis factor (TNF)-&agr; may be able to slow or even arrest progressive joint destruction in patients with RA.*The latest clinical efficacy and safety data with 2 biological agents that neutralise the activity of TNF-&agr;, Immunex's TNFR-Fc p75 fusion protein [‘Enbrel’] and Centocor's infliximab [CenTNF, ‘Avakine’], were presented at the 1997 Annual Meeting of the American College of Rheumatolog [Washington DC, US; November 1997].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 10-10
&NA;,
Preview
|
PDF (746KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
Post-MIuse &bgr;-blockers rather than calcium antagonists |
|
Inpharma Weekly,
Volume &NA;,
Issue 1123,
1998,
Page 11-11
&NA;,
Preview
|
PDF (746KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|